Alexis Génin heads the Research & Technology Development office at ICM, since 2010. He holds a PhD in neurosciences.
After a research assignment in Asia and collaborative programs with the pharmaceutical industry, he took responsibility of international business development operations for a Paris-based medtech & diagnostic company.
Alexis participated to the establishment of INSERM-Transfert, a spin-off company from INSERM, in charge of Tech transfer, before joining the ICM at its start.
Valérie Fonteny is Office Manager, in charge of the administrative management of partnerships and patents, and of logistical and organizational issues.
She holds a tourism technician’s certificate (national interpreter-guide) and an art history postgraduate diploma.
She worked at the National Cancer Institute as an executive assistant, then as a project manager with the director of research. Previously, she worked at Orphanet, the portal of rare diseases and orphan drugs.
Manon Bonnefond is business events manager, in charge of organizing R&D events, learning expeditions and other events with industry partners.
She holds a MBA is Communication and Health. She worked previously with JANSSEN / J&J.
Claire Roudot is Biotech Development Manager at ICM. She holds a Master of Engineering in Biotechnologies from ESBS and a Master in Biopharmaceutical management from ESCP Europe Business School.
Claire previously worked in R&D at New England Biolabs in Boston and in a strategic consulting firm. Then, she joined the Business Development & Licensing department at Sanofi where she identified collaborative opportunities and negotiated several early-stage deals with academic and biotech partners.
Audrey Montersino is Development Manager at ICM, in the context of the FINDMED consortium.
She holds a PhD in Neuroscience and an Executive Master degree in “Strategy and management of health industry”. After a post-doc at Temple University (USA) when she investigated innovative therapeutic approaches to nerve regeneration, she worked as a scientist at drug company Servier, then as a consultant for pharma at IQVIA.
Benjamin François is a drug development engineer. He holds a Biotechnology Engineering diploma from EBI in Research and Development.
He worked as a research engineer at the Atomic Energy Commission on Prion diseases, and had a second experience in a private CRO as a preclinical test engineer.
Benjamin is in charge of preclinical testing of potential new medicinal products developed by research teams at ICM.
Romain Gombert is the Medtech Development Manager and manages ICM’s livinglab, cLLAPS.
He graduated with one Master degree in mechatronics systems for rehabilitation at Pierre and Marie Curie University (UPMC Paris) and Università degli Studi di Brescia (UNIBS – Italy) and a second in management of technologies and innovation at Paris Dauphine and Mines ParisTech. He built his expertise in innovative project management across the Living-Lab LUSAGE at Broca hospital and several Innovation Labs in Europe.
Pierre Tissier is a prototyping engineer at the ICM. He designs and produces technologies for research purposes and for patient care. He also provides access to the latest prototyping technologies (3D printers, laser cutting machine…) to researchers and industry partners.
Pierre holds a Master degree in robotic engineering from the mechanical engineering school SupMeca.
Pierre Georges-François has been working in the field of clinical research clinical for more than 15 years, 10 years of which having been spent within the French Pharma of Ipsen, where he managed all kind of clinical trials in various therapeutic areas, from Phase I first-in-Man clinical trials to pivotal phase III trials.
Pierre is in charge of developing ICM’s clinical research collaborations with Pharma, biotech and MedTech industry players.
Louise-Laure MARIANI (MD, PhD) is a Neurologist and Neuroscientist, with a specialization in neuropharmacology. She also has an expertise in neurological disorders, such as Parkinson's disease, cerebellar ataxia, other movement disorders and neurogenetics. Dr MARIANI works as a neuropharmacologist at the Pitié-Salpêtrière Hospital (Paris, Sorbonne University), and as a clinician at the Clinical Investigation Center of the Paris Brain Institute. She works in close collaboration with the various french reference centers for neurological diseases.
Julien Elric is the iPEPS-ICM incubator manager.
He holds a PhD in cell biology from Pasteur Institut. After graduating from INSEAD, he joined the business development and licensing department at Curie Institut, in charge of international development.
His activities at ICM range from providing support for startups development to fostering international innovation and entrepreneurship.
Louise Remigereau is in charge of logistical and organizational aspects of the iPEPS-ICM incubator.
She holds a bachelor in communication and a master’s degree in event management. She has always worked in connection with small- and medium-size companies.
Eartha Mabida Din is the e-health Program Manager iPEPS-ICM @STATIONF.
Prior joining ICM, she has been working in the US to help medtech and e-health companies on the North American market at Business France.
She is graduated from ESSEC Business School and UPMC Sorbonne Universities.
Damien Salauze is entrepreneur in residence at IPEPS-ICM.
He holds a PharmD, PhD, as well as an MBA from INSEAD. He first worked at Rhône-Poulenc / Aventis in drug-development position and marketing positions, and then joined the venture-capital firm Auriga Partners. He there became CEO of 2 start-up companies : Novagali Pharma then Sepal Pharma. He also headed the Office of technology Transfer at Curie Institut. Damien serves as equity manager for ICM (in addition to heading of the FINDMED consortium, coordinated by ICM).
Ségolène Aymé is rare disease expert in residence at ICM, as Emeritus director of Research at INSERM.
She was a medical geneticist and epidemiologist. She founded Orphanet and the Orphanet Journal of Rare Diseases. She held several international positions in the field of rare diseases and orphan drugs research and policy.
Ségolène contributes to the development of the ICM activities in favor of the rare neurological diseases.